NLRP3 Inflammasome Activation in Hemodialysis and Hypertensive Patients with Intact Kidney Function.
Adult
Aged
Body Mass Index
Diabetes Mellitus
/ immunology
Female
Humans
Hypertension
/ immunology
Inflammasomes
/ immunology
Interleukin-1beta
/ genetics
Kidney
Kidney Failure, Chronic
/ immunology
Male
Middle Aged
Monocytes
NLR Family, Pyrin Domain-Containing 3 Protein
/ immunology
Overweight
/ immunology
Pyroptosis
Renal Dialysis
caspase-1
hemodialysis
hypertension
inflammation
monocytes
Journal
Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765
Informations de publication
Date de publication:
26 10 2020
26 10 2020
Historique:
received:
11
09
2020
revised:
16
10
2020
accepted:
22
10
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
9
7
2021
Statut:
epublish
Résumé
Hypertension is not only an integrative characteristic of hemodialysis (HD) patients but is also very common in the general population. There is evidence that the inflammatory cytokine IL-β, regulated by the NLRP3 inflammasome via caspase-1, contributes to the hypertensive setting. Therefore, we investigated in an observational pilot study whether IL-1β secretion and inflammatory cell death (pyroptosis) are different in HD and hypertensive patients with intact kidney function. Twenty HD patients were age-, gender-, and diabetes-mellitus-matched to patients with hypertension and intact kidney function. Caspase-1 activity and pyroptosis rates were measured by flow cytometry. IL-1β was determined by qPCR and the ELISA technique. The inflammatory status (CRP) did not differ between both groups; however, the body mass index, a classical cardiovascular risk factor, was significantly elevated in blood pressure (BP) patients. BP patients had a higher frequency of caspase-1-positive monocytes compared to HD (
Identifiants
pubmed: 33114648
pii: toxins12110675
doi: 10.3390/toxins12110675
pmc: PMC7693185
pii:
doi:
Substances chimiques
Inflammasomes
0
Interleukin-1beta
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
NLRP3 protein, human
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Références
Science. 2018 Nov 23;362(6417):956-960
pubmed: 30467171
J Immunol. 2015 Jan 1;194(1):455-62
pubmed: 25404358
J Immunol. 2014 Feb 15;192(4):1835-46
pubmed: 24453255
Am Heart J. 1999 Nov;138(5 Pt 2):S419-20
pubmed: 10539839
Front Immunol. 2018 Dec 11;9:2918
pubmed: 30619282
Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8067-72
pubmed: 18523012
Cardiovasc Res. 2019 Mar 15;115(4):776-787
pubmed: 30357309
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):775-80
pubmed: 24379360
Hypertension. 2001 Sep;38(3):399-403
pubmed: 11566912
J Exp Med. 2019 Nov 4;216(11):2453-2465
pubmed: 31548300
Eur Heart J. 2010 Feb;31(3):369-76
pubmed: 19687164
Cell. 2014 May 22;157(5):1013-22
pubmed: 24855941
ISRN Inflamm. 2013 Dec 22;2013:139239
pubmed: 24455420
Int J Mol Sci. 2020 Feb 20;21(4):
pubmed: 32093389
Int J Mol Sci. 2019 Jul 06;20(13):
pubmed: 31284572
Biochim Biophys Acta. 2013 Dec;1833(12):3448-3459
pubmed: 23770045
Basic Res Cardiol. 2017 Dec 09;113(1):5
pubmed: 29224086
Proc Natl Acad Sci U S A. 2007 May 8;104(19):8041-6
pubmed: 17483456
Lancet. 2005 Jan 15-21;365(9455):217-23
pubmed: 15652604
J Immunol Res. 2018 Apr 8;2018:5702103
pubmed: 29850631
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):2835-40
pubmed: 25730877
Arch Intern Med. 2002 Sep 9;162(16):1867-72
pubmed: 12196085
Vasc Health Risk Manag. 2009;5:713-22
pubmed: 19756163
PLoS One. 2015 Mar 23;10(3):e0122272
pubmed: 25798846
Am J Hypertens. 2014 Nov;27(11):1327-37
pubmed: 25150828
J Immunol. 2015 Dec 15;195(12):5718-24
pubmed: 26546608
Front Immunol. 2014 Nov 17;5:553
pubmed: 25452754
J Transl Med. 2019 May 22;17(1):169
pubmed: 31118060
Br J Pharmacol. 2014 Dec;171(24):5589-602
pubmed: 25117218
Am J Kidney Dis. 2019 Jul;74(1):120-131
pubmed: 30898362
Eur Heart J. 2016 Nov 7;37(42):3232-3245
pubmed: 27523477
Cardiovasc Ther. 2009 Fall;27(3):181-6
pubmed: 19689617